

Lectures/Grand Rounds by Invitation:

- September 2016 John Duda, MD presented "Can Living Micro-Tissue Engineered Axonal Tracts Reconstruct the Nigrostriatal Pathway in PD?" 4th World Parkinson Congress, Portland, Oregon
- September 2016 John Duda, MD presented "Is there a role for nutrition altering progression of PD?" 4th World Parkinson Congress, Portland Oregon
- September 2016 John Duda, MD presented "Nutritional Considerations in Parkinson's Disease", 2016 National VA Parkinson's Disease Consortium Meeting, Portland, Oregon
- September 2016 James Morley, MD, PhD "Drug-induced parkinsonism: a canary in the coal mine?". National VA Parkinson's disease Consortium Meeting. Portland, OR
- September 2016 Daniel Weintraub, MD presented "Management of Psychiatric complications of PD", National VA Parkinson's Disease Consortium Conference; Portland, OR
- May 2016 Daniel Weintraub, MD presented "PPMI Cognitive-Behavioral Working Group", Parkinson's Progression Markers Initiative (PPMI) Annual Meeting; New York, New York
- May 2016 Daniel Weintraub, MD presented "Cognitive and Psychiatric Burden in Parkinson's Disease", 9th World Congress for Neurorehabilitation; Philadelphia, Pennsylvania
- April 2016 Daniel Weintraub, MD presented "Cognitive Impairment in Parkinson's Disease", Lewy Bodies and Parkinson's Dementia: Unmet Needs and Emerging Treatments, King's College; London, England
- April 2016 Daniel Weintraub, MD presented "Update on Cognition in Lewy Body Disorders", PSP/Lewy Body Disease Think Tank Annual Symposium, University of Florida Center for Movement Disorders and Neurorestoration; Gainesville, Florida
- April 2016 Michelle Fullard, MD platform presentation "Olfactory impairment predicts cognitive decline in early Parkinson's disease" at the American Academy of Neurology, Vancouver, BC, Canada

March 2016	Daniel Weintraub, MD presented "Recent Developments in Parkinson Disease Neuropsychiatry", The Cleveland Clinic and Parkinson Study Group 4th Annual Symposium Shaping the Management of Parkinson's Disease: Comprehensive Review of Discoveries and Clinical Trials; Las Vegas, Nevada
March 2016	Daniel Weintraub, MD presented "The Neuropsychiatry of Parkinson's Disease: Recent Developments", Neuroscience Education Institute Synapse Conference; Jersey City, New Jersey
February 2016	Daniel Weintraub, MD presented "Effect of L-dopa on non-motor symptoms in Parkinson's disease: Non-motor complications in Parkinson's disease", Centricity Series: Biomedical Research Symposia, The Feinstein Institute for Medical Research; Manhasset, New York
November 2015	Daniel Weintraub, MD presented: "The Neuropsychiatry of Parkinson's Disease: Recent Developments", Geriatric Medicine Grand Rounds; University of Pennsylvania School of Medicine; Philadelphia, Pennsylvania
November 2015	Daniel Weintraub, MD presented: "Penn Udall Center Update", 7th Annual Udall Research Symposium and Breakfast, University of Pennsylvania School of Medicine; Philadelphia, Pennsylvania

Articles

1. Pigott, K., Rick, J., Xie, S.X., Hurtig, H., Chen-Plotkin, A., Duda, J.E., Morley, J.F., Chahine, L., Dahodwala, N., Akhtar, R.S., Siderowf, A., Trojanowski, J.Q., Weintraub, D.: Longitudinal study of normal cognition in Parkinson's disease. *Neurology* 85: 1276-82, 2015.
2. Brennan, L., Siderowf, A., Rubright, J.D., Rick, J., Dahodwala, N., Duda, J.E., Hurtig, H., Stern, M., Xie, S.X., Rennert, L., Karlawish, J., Shea, J.A., Trojanowski, J.Q., Weintraub, D.: The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. *Parkinsonism and Related Disorders* 25: 21-6, 2016.
3. Brennan, L., Siderowf, A., Rubright, J.D., Rick, J., Dahodwala, N., Duda, J.E., Hurtig, H., Stern, M., Xie, S.X., Rennert, L., Karlawish, J., Shea, J.A., Trojanowski, J.Q., Weintraub, D. : Development and initial testing of The Penn Parkinson's Daily Activities Questionnaire. *Movement Disorders* 31: 126-34, 2016
4. Marras, C., Alcalay, R.N., Caspell-Garcia, C., Coffey, C., Chan, P., Duda, J.E., Facheris, M.F., Fernández-Santiago, R., Ruiz-Martínez, J., Mestre, T., Saunders-Pullman, R., Pont-Sunyer, C., Tolosa, E., Waro, B., and the MJFF LRRK2 Cohort Consortium: Motor and non-motor heterogeneity of LRRK2-related and idiopathic Parkinson Disease. *Movement Disorders* 31: 1192-202, 2016

5. Toledo, J.B., Gopal1, P., Raible1, K., Irwin1, D.J., Brettschneider, J., Sedor, S., Watts, K., Boluda, S., Grossman, M., Van Deerlin, V.M., Lee, E.B., Arnold, S.E., Duda, J.E., Hurtig, H., Lee, V.M-Y., Trojanowski, J.Q.: Pathological α -synuclein Distribution in Subjects with Coincident Alzheimer's and Lewy Body Pathology. *Acta Neuropathologica* 131: 393-409, 2016.
6. Wilkinson, J.R., Spindler, M., Wood, S.M., Marcus, S.C., Weintraub, D., Morley, J.F., Stineman, M.G., Duda, J.E.: High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study. *Neurology Clinical Practice* 6: 241-51, 2016.
7. Hassan A, Ahlskog JE, Matsumoto J, Milber J, Bower J, Wilkinson JR. Orthostatic Tremor: Clinical, Electrophysiologic and Treatment Findings in 184 Patients. *Neurology*. 2016 Feb 2;86(5): 458-64.
8. Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawska B, Mamikonyan E, Kales HC. Association of Antipsychotic Use With Mortality Risk in Patients Parkinson Disease. *JAMA Neurol* 2016 May 1;73(5):535-41.
9. Cullen, D.K., Harris, J.P., Browne, K.D., Wolf, J.A., Duda, J.E., Meaney, D.F., Margulies, S.S., Smith, D.H.: A Porcine Model of Traumatic Brain Injury via Head Rotational Acceleration. *Methods in Molecular Biology* 1462: 289-324, 2016
10. Brennan, L., Pantelyat, A., Duda, J.E., Morley, J.F., Weintraub, D., Wilkinson, J.R., Moberg, P.J. : Memantine and Cognition in Parkinson's Disease Dementia/Dementia with Lewy Bodies: A Meta-Analysis. *Movement Disorders Clinical Practice* in press.
11. Fullard, M.E., Tran, B., Xie, S.X., Toledo, J.B., Scordiab, C., Linder, C., Purri, R., Weintraub, D., Duda, J.E., Chahine, L.M., Morley, J.F.: Olfactory impairment predicts cognitive decline in early Parkinson's disease. *Parkinsonism and Related Disorders* in press.
12. Mischley, L.K., Conley, K.E., Shankland, E.G., Kavanagh, T.J., Rosenfeld M.E., Duda, J.E., White, C.C., Wilbur, T.K., De La Torre1, P.U., Padowski, J.M.: Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease. *npj Parkinson's Disease* in press.
13. Roalf, D.R., Moore, T.M., Wolk, D.A., Arnold, S.E., Mechanic-Hamilton, D., Rick, J., Kabadi, S., Ruparel, K., Chen-Plotkin, A.S., Chahine, L.M., Dahodwala, N.A., Duda, J.E., Weintraub, D.A., Moberg, P.J.: Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. *Journal of Neurology, Neurosurgery and Psychiatry* in press.
14. Shah, S.P. and Duda, J.E.: Dietary modifications in Parkinson's disease: A neuroprotective intervention? *Medical Hypotheses* 85: 1002-5, 2015
15. Boeve, BF., Dickson, D.W., Duda, J.E., Ferman, T.J., Galasko, D.R., Galvin, J.E., Goldman, J.G., Growdon, J.H., Hurtig, H.I., Kaufer, D.I., Kantarci, D., Leverenz, J.B., Lippa, C.F., Lopez, O.L., McKeith, I.G., Singleton, A.B., Taylor, A., Tsuang, D., Weintraub, D., Zabetian, C.P.: Arguing Against Proposed Definition Changes of PD. *Movement Disorders* in press.
16. Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, Mulsant BH, Munro CA, Newell JA, Pawluczyk S, Pelton G, Pollock BG, Porsteinsson AP, Rabins PV, Rein L, Rosenberg PB, Shade D, Weintraub D, Yesavage J, Lyketsos CG, for the CitAD Research Group. Heterogeneity of treatment response to citalopram for Alzheimer disease patients with aggression or agitation: the CitAD randomized clinical trial. *The American Journal of Psychiatry* 173:465-472, 2016.

17. Peters ME, Vaidya V, Drye LT, Devanand DP, Mintzer JE, Pollock BG, Porsteinsson AP, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Avramopoulos D, for the CitAD Research Group. Citalopram for the treatment of agitation in Alzheimer's dementia: genetic influences. *Journal of Geriatric Psychiatry and Neurology* 29;59-64, 2016.
18. Terrelonge M, Marder KS, Weintraub D, Alcalay RN. CSF β -amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. *Journal of Molecular Neuroscience* 58;88-92, 2016.
19. Akhtar RS, Xie SX, Laura Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-beta positron emission tomography imaging of Alzheimer's pathology in Parkinson's disease dementia. *Movement Disorders Clinical Practice* 3;367-375, 2016.
20. Moelter ST, Weintraub D, Mace L, Cary M, Sullo E, Xie SX, Karlawish J. Research consent capacity varies with executive function and memory in Parkinson's disease. *Movement Disorders* 31;414-417, 2016.
21. Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, Rosenberg PB, Madore M, Chao SZ, Devanand DP, Drye LT, Mintzer JE, Pollock BG, Porsteinsson AP, Schneider LS, Shade DM, Weintraub D, Lyketsos CG, Noda A, for the CitAD Research Group. *Journal of Psychiatric Research* 74:17-21, 2016.
22. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu S-C, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. *Movement Disorders* 31;95-102, 2016.
23. Chahine L, Weintraub D, Hawkins KA, Siderowf A, Eberly S, Oakes D, Seibyl J, Stern MB, Marek K, Jennings D, and the PARS Investigators. Cognition in individuals at risk for Parkinson's: Parkinson Associated Risk Syndrome Study findings. *Movement Disorders* 31;86-94, 2016.
24. Smith KM, Xie SX, Weintraub D. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. *Journal of Neurology, Neurosurgery and Psychiatry* 87;864-870, 2016.
25. Ragnhild E, Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D. Associations between cerebrospinal fluid biomarkers and cognition in early untreated Parkinson's disease. *Journal of Parkinson's Disease* 5;783-792, 2015.
26. Berlyand Y, Weintraub D, Xie SX, Mellis IA, Doshi J, Rick J, McBride J, Davatzikos C, Shaw LM, Hurtig H, Trojanowski JQ, Chen-Plotkin AS. An Alzheimer's disease-derived biomarker signature identifies Parkinson's disease patients with dementia. *PLoS ONE* 11;e0147319, 2016.
27. Biundo R, Weis L, Bostantjopoulou S, Stefanova E, Falup-Pecurariu C, Kramberger M, Geurtzen GJ, Antonini A, Weintraub D, Aarsland D, on behalf of the DLB consortium. MMSE and MoCA feasibility in Parkinson's disease and Dementia with Lewy bodies: A multicenter 1-year follow-up study. *Journal of Neural Transmission* 10.1007/s00702-016-1517-6, 2016.
28. Leonpacher A, Peters ME, Drye LT, Makino KM, Newell J, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP, for the CitAD Research Group. Effects of citalopram

- on neuropsychiatric symptoms in Alzheimer's dementia: Evidence from the CitAD Study. *American Journal of Psychiatry* 173:473-480, 2016.
- 29. Lim N, Swanson C, Cherg H-R, Unger T, Xie S, Weintraub D, Marek K, Siderowf A, Trojanowski J, Chen-Plotkin A. Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. *Annals of Clinical and Translational Neurology* 10.1002/acn3.299, 2016.
 - 30. Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A, for the MODERATO investigators. Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo-controlled trial. *Movement Disorders* 31;709-714, 2016.
 - 31. Kang J-H, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligorska T, Peggy T, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM. CSF biomarkers associated with disease heterogeneity in early Parkinson disease; The Parkinson's Progression Markers Initiative study *Acta Neuropathologica* 10.1007/s00401-016-1552-2, 2016.
 - 32. Rizos A , Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Karlsen KR, Grilo M, Odin P, Chaudhuri KR, on behalf of EUROPAR and the IPMDS Non Motor PD Study Group. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. *European Journal of Neurology* 23;1255-1261, 2016.
 - 33. Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videncovic A, Del Riva P, Weintraub D. Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. *Parkinsonism and Related Disorders* 10.1016/j.parkreldis.2016.03.006, 2016.
 - 34. Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier F, Moszer I, Brice A, Singleton AB, Corvol J-C. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. *Journal of Neurology, Neurosurgery, and Psychiatry* 10.1136/jnnp-2015-312848, 2016.
 - 35. Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, Weintraub D. Impulse control disorder-related behaviours during long-term rotigotine treatment: a post hoc analysis. *European Journal of Neurology* 0.1111/ene.13078, 2016.
 - 36. Friedman J, Beck J, Chou K, Clark G, Fagundes C, Goetz C, Herlofson K, Kluger B, Krupp L, Lang A, Lou J-S, Marsh L, Newbould A, Weintraub D. Fatigue in Parkinson's disease: report from a multidisciplinary symposium. *npj Parkinson's Disease* 2:15025, 2016.
 - 37. Kluger BM, Herlofson K, Chou KL, Lou J-S, Goetz CG, Lang AE, Weintraub D, Friedman J. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. *Movement Disorders* 31;625-631, 2016.
 - 38. Martinez-Martin P, Leentjens AFG, de Pedro-Cuesta J, Chaudhuri KR, Schrag AE, Weintraub D. Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. *Movement Disorders* 31:270-279, 2016.
 - 39. Armstrong MJ, Weintraub D. The case for antipsychotics in dementia with Lewy bodies. *Movement Disorders Clinical Practice* 10.1002/mdc3.12383,2016.

40. Ho T, Bies R, Mulsant BH, Devanand DP, Mintzer JE, Porsteinsson AP, Schneider LS, Weintraub D, Yesavage J, Drye LT, Munro CA, Shadé DM, Lyketsos C, Pollock BG. R-and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. *British Journal of Clinical Pharmacology* (in press).
41. Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu S-C, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP. The Influence of GBA mutations and the E326K Polymorphism on Rate of Motor Progression in Parkinson Disease. *JAMA Neurology* (in press).
42. van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, on behalf of the E-DLB consortium. CSF AD biomarkers across the spectrum of Lewy body diseases: Results from a large multicenter cohort. *Journal of Alzheimer's Disease* (in press).
43. James F. Morley, Gang Cheng , Jacob G. Dubroff , Stephanie Wood, Jayne R. Wilkinson and John E. Duda MD.Olfactory impairment predicts underlying dopaminergic deficit in presumed drug-induced parkinsonism. *Mov Dis Clin Pract* (in revision)
44. Ibolja, C., Stein, D., Ahlers, S.T., Curley, K., Duda, J., Ikonomovic, M.D., Iverson, G.L., Kobeissy, F., Koliatsos, V.E., Koroshetz, W., Leggieri, M., Pacifico, A., Smith, D.H., Swanson, R., Thompson, F., Tortella, F., Elder, G.A.: Preclinical Modeling of Militarily Relevant Traumatic Brain Injuries: Challenges and Recommendations for Future Directions. *Brain Injury* In submission.
45. Struzyna, L.A., Browne, K.D., Brodnik, Z.D., Burrell, J.C., Harris, J.P., Chen, H.I., Wolf, J.A., Duda, J.E., España, R.A., Cullen, D.K. Transplantable dopaminergic micro-tissue engineered neural networks to recapitulate the nigrostriatal pathway in Parkinson's disease. In submission.
46. Ugras, S., Luk, K., Luna, E., Yocum, A.K., Ding, H., McKennan, C., Seeholzer, S., Martinez, D., Brown, D., Duda, J.E., Evans, P., Ischiropoulos, H. Quantitative proteomic analysis reveals upregulation of the immunoproteasome in response to endogenous α -synuclein aggregation. In submission.
47. Ross GW, Abbott RD, Petrovitch H, Duda J, Tanner CM, Zarow C, Uyehara-Lock,J, Masaki K, Launer L, White LR Association of brain organochlorines with Lewy pathology. In submission.
48. Irwin, D.J., Grossman, M., Weintraub, D., Hurtig, H.I., Duda, J.E., Xie, S.X., Lee, E.B., Van Deerlin, V.M., Lopez, O.L., Kofler, J.K., Nelson, P.T., Woltjer, R., Quinn, J.F., Kaye, J., Leverenz, J.B., Tsuang, D., Longfellow, K., Yearout, D., Kukull, W., Keene, C.D., Montine, T.J., Zabetian, C.P., Trojanowski, J.Q. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. *Lancet Neurology*, in press.

Chapters:

1. Doty, R.L., Hawkes, C.H., Good, K.P., Duda, J.E.: Odor perception and neuropathology in neurodegenerative diseases and schizophrenia. *Handbook of Olfaction and Gustation - Third Edition*. Doty, R.L. (eds.). John Wiley & Sons, Inc. Page: 403-452, 2015.
2. Cullen, D.K., Harris, J.P., Browne, K.D., Wolf, J.A., Duda, J.E., Meaney, D.F., Margulies, S.S., Smith, D.H.: A Porcine Model of Closed-Head Rotational Acceleration Induced Traumatic Brain Injury Based on the HYGE Device. *Injury Models of Central Nervous System: Traumatic Brain Injury, Methods in Molecular Biology* Dixon, Kobeissy, Hayes and Mondello (eds.). in press.
3. Weintraub D, Chahine, LM. Lessons and Challenges of Trials for Cognitive and Behavioral Complications of Parkinson's Disease. In: Galvez-Jimenez N, Fernandez HH, Espay AJ, Fox SH, eds. *Parkinson's Disease: Current and Future Therapeutics and Clinical Trials*. Cambridge: Cambridge University Press, 2016:325-336.
4. Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, MPH, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP. Arguing against the proposed definition changes of PD [editorial]. *Movement Disorders* 10.1002/mds.26721, 2016.
5. Browne, K.D., Harris, J.P., Kuo, E., Brown, D.P., Wolf, J.A., Duda, J.E., Cullen, D.K.: Periods of Increased Biomechanical Vulnerability to Repetitive Mild Traumatic Brain Injury Based on Neuronal Plasmalemmal Disruptions. *Proceedings of the International Research Council on Biomechanics of Injury*. in review

Poster Presentations

September 2016 James F. Morley, Gang Cheng, Jacob G. Dubroff, Stephanie Wood, Jayne R. Wilkinson and John E. Duda: Hyposmia predicts underlying dopaminergic deficit in drug-induced Parkinsonism 4th World Parkinson Congress. Portland, OR

September 2016 Dobkin RD, Durland JL, Nessel K, Gara M, Menza M, Mavandadi, Weintraub D, Marsh L, Stanley MA, Biglan KM, Interian AI. Telehealth cognitive behavioral therapy for depression inParkinson's disease: Overview and design of two new randomized-controlled clinical trials. 30th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, Parkinson Study Group: Portland, United States

September 2016 Espay AJ, Coffey CS, Foster ED, Uribe L, Caspell-Garcia CJ, Weintraub D. Dopaminergic medications and mood enhancement in Parkinson disease. 30th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, Parkinson Study Group: Portland, United States.

September 2016 Weintraub D, Macklin E, Cartaya A, Wesnes K, Eberling J, Kenney C, Cravotto K, Schwarzschild M, Litvan I, Pothier L, Fernandez H. SYN120, a dual 5-HT6/5-HT2A antagonist, for Parkinson's disease dementia (SYNAPSE): Study design and partial blinded data. 30th Annual

Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, Parkinson Study Group: Portland, United States

September 2016 Duda, J.E., Struzyna, L.A., Browne, K.D., Burrell, J., Chen, H.I., Cullen, D.K.: Can living micro-tissue engineered axonal tracts reconstruct the nigrostriatal pathway in PD? Poster presented at the 4th World Parkinson Congress, Portland, Oregon.

September 2016 Duda, J.E., Keating, C., Kamarck, M., Harris, J.P., Browne, K.D., Wolf, J.A., Cullen, D.K.: Diffuse brain injury in swine causes plasmalemmal disruption and α -Synuclein over-expression in the substantia nigra. Poster presented at the 4th World Parkinson Congress, Portland, Oregon.

June 2016 Wofford, K.L., Browne, K.D., Harris, J.P., Meitus, C.J., Brown, D.P., Grovola, M.R., Kuo, E., Wolf, J.A., Duda, J.E., Spiller, K.L., Cullen, D.K.: Rapid microglial activation near injured neurons following diffuse brain injury in swine. Poster presented at the National Neurotrauma Symposium, June 26-29, Lexington, KY.

June 2016 B.L. Deck, J. Rick, S. Xie, A. Chen-Plotkin, J. Morley, J. Duda, L. Chahine, N. Dahodwala, R. Akhtar, J. Trojanowski, & D. Weintraub: The effect of statin use on cognition in Parkinson's disease. 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany.

June 2016 Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF: Olfactory impairment predicts cognitive decline in early Parkinson's disease. University of Pennsylvania Institute on Aging SYLVAN M. COHEN RETREAT & POSTER SESSION

June 2016 Laura Brennan, Kathryn Devlin, Sharon Xie, Dawn Mechanic-Hamilton, Baohan Tran, Howard Hurtig, Alice Chen-Plotkin, Lama Chahine, James F. Morley, John E. Duda, David R. Roalf, Nabila Dahodwala, Jacqueline Rick, John Q. Trojanowski, Paul J. Moberg, Daniel Weintraub : Neuropsychological subgroups in non-demented Parkinson's disease: A latent class analysis. 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany

June 2016 Rachael Purri, Laura Brennan, Jacqueline Rick, Lama Chahine, Nabila Dahodwala, Alice Chen-Plotkin, John E. Duda, James F. Morley, Rizwan S. Akhtar, John Q. Trojanowski, & Daniel Weintraub: Cognitive complaint in Parkinson's disease patients with normal cognition 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany

June 2016 Chahine, L., Xie, S., Smith, K., Scordia, C., Purri, R., Linder, C., Duda, J., Dahodwala, N. : Supplement use in PD is associated with delayed initiation of dopaminergic therapy. 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany

June 2016 M.E. Fullard, D.P. Thibault, A. Hill, J. Fox, A.W. Willis: Underutilization of physiotherapy for Parkinson's disease in the United States. 20th International Congress of Parkinson's Disease and Movement Disorders. Berlin, Germany

April 2016 Hassan A, Ahlskog JE, Matsumoto J, Milber J, Bower J, Wilkinson JR. Orthostatic Tremor: Clinical, Electrophysiologic and Treatment Findings in 184 Patients. (Presented at the American Academy of Neurology, Vancouver, BC, Canada)

October 2015 James F. Morley, Gang Cheng, Jacob G. Dubroff, Jayne R. Wilkinson, John E. Duda. Can drug-induced Parkinsonism reveal pre-motor Parkinson disease? Penn Center for Neurodegenerative Disease Research 15th Annual Marian S. Ware Research Retreat. 10/2015. Won award for best poster (3rd Place)

October 2015 Katiyar, K. S., Winter, C. C., Hernandez, N. S., Harris, J. P., Struzyna, L. A., Cullen, D. K. : Tissue engineered living scaffolds consisting of aligned astrocytes for nervous system repair. Poster presentation at the Biomedical Engineering Society Annual Meeting, Tampa, FL

October 2015 Struzyna, L. A., Harris, J. P., Browne, K. D., Burrell, J. C., Chen, H. I., Cullen, D. K. : Reconstructing the nigrostriatal pathway with living micro-tissue engineered axonal tracts. Poster presentation at the Biomedical Engineering Society Annual Meeting, Tampa, FL

Platform Presentation

Daniel Weintraub, MD: "Management of Psychiatric Complications", National VA Parkinson's Disease Consortium Meeting; Portland Oregon, September, 2016.

Daniel Weintraub, MD: "Cognitive and Psychiatric Burden in Parkinson's Disease", 9th World Congress for Neurorehabilitation; Philadelphia, Pennsylvania, May, 2016.

Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF: Olfactory Function Predicts Cognitive Deficits and Decline in Early Parkinson's Disease. 68th Annual Meeting of the American Academy of Neurology April 2016

Daniel Weintraub, MD: "Recent Developments in Parkinson Disease Neuropsychiatry", The Cleveland Clinic and Parkinson Study Group 4th Annual Symposium Shaping the Management of Parkinson's Disease: Comprehensive Review of Discoveries and Clinical Trials; Las Vegas, Nevada, March, 2016.

List of Current Studies

Predictors of Recovery in Drug-Induced Parkinsonism: Relationship to Idiopathic Parkinson's Disease – PI - James Morley, MD, PhD

Degenerative Nigrostriatal Dysfunction in Drug-Induced Parkinsonism – PI - James Morley, MD, PhD

Markers for Diagnosis and Prognosis in Parkinson's Disease –PI- James Morley, MD, PhD

Effect of Exercise on Recovery in Drug-Induced Parkinsonism and Parkinson Disease-PI- James Morley, MD, PhD

Effect of Balance Based Torso Weighting on Gait and Parkinsonism - James Morley, MD, PhD

Exercise and DIP and PD Protocol (#823910: UPENN DIPEX)- PI- James Morley, MD, PhD

Predictors of Clinical Recovery in Drug Induced Parkinsonism: Relationship to Underlying Dopaminergic Denervation- PI- James Morley, MD, PhD

The Role of Bitterome and Microbiome in Parkinson's Disease – PI-John Duda, MD

"Living Electrodes" Using Tissue Engineered Axonal Tracts to Probe and Modulate the CNS – Co PI-John Duda, MD

Restoring the nigrostriatal pathway with living micro-tissue engineered axonal tracts –Co-PI-John Duda, MD

Chronic neurodegenerative and neurophysiological sequela of closed-head TBI-PI – John Duda, MD